Madrigal Pharmaceuticals (MDGL) Change in Cash (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Change in Cash data on file, last reported at $28.4 million in Q1 2026.

• Change in Cash for Q1 2026 came in at $28.4 million, down 66.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.5 million (up 110.04% YoY), and the FY2025 annual result was $98.8 million, up 1835.03% from the prior year.
• Change in Cash climbed to $28.4 million in Q1 2026 per MDGL's latest filing, from -$96.9 million in the prior quarter.
• Over five years, Change in Cash peaked at $522.6 million in Q1 2024 and troughed at -$261.9 million in Q3 2024.
• A 5-year average of $11.5 million and a median of $6.0 million in 2022 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2022 and 2023: Change in Cash surged 2209.33% in 2022, then plunged 3729.49% in 2023.
• A 5-year view of Change in Cash shows it stood at $272.2 million in 2022, then plunged by 86.09% to $37.9 million in 2023, then slumped by 450.41% to -$132.7 million in 2024, then gained by 26.95% to -$96.9 million in 2025, then jumped by 129.31% to $28.4 million in 2026.
• Business Quant data shows MDGL's Change in Cash at $28.4 million in Q1 2026, -$96.9 million in Q4 2025, and $109.5 million in Q3 2025.